Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival

Mohammad H. Dastjerdi, Daniel R. Saban, Andre Okanobo, Nambi Nallasamy, Zahra Sadrai, Sunil K. Chauhan, Amir R. Hajrasouliha, Reza Dana

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Purpose. To investigate whether corneal graft survival could be improved by topical or subconjunctival bevacizumab in a murine model of vascularized high-risk corneal transplantation. Methods. Before corneal transplantation, intrastromal sutures were placed for 2 weeks in the corneas of BALB/c mice, inducing intense angiogenesis. Allogeneic corneal transplantation was performed using C57BL/6 donor mice. Topical bevacizumab (2.5%) was delivered 3 times a day for 3 weeks in one treatment group, and 0.02 mL (0.5 mg) bevacizumab was injected subconjunctivally at days 0, 4, 8, and 15 after transplantation in the other treatment group. The control group received no treatment. Grafts were examined twice a week for 8 weeks by slit-lamp microscopy and were photographed once a week by slit-lamp digital camera and scored for opacity. For assessment of corneal neovascularization (NV), a quantitative method was used to measure three primary metrics including neovascular area, vessel caliber, and neovessel invasion area. Results. Both topical and subconjunctival bevacizumab treatment reduced neovascular area and vessel caliber; however, the regression of corneal NV was more profound when treated subconjunctivally. The mean percentage reduction of neovascular area was 55% (P < 0.05) by week 8 in the subconjunctival treatment group and 33% (P=0.15) in the topical group. Only subconjunctival bevacizumab treatment resulted in significant regression of neovessel invasion area (P < 0.05). All corneal transplants in both the control and the topical groups were rejected by 4 weeks after transplantation. However, in the subconjunctival treatment group, 33% of corneal grafts survived (P < 0.01). Conclusions. Subconjunctival bevacizumab may offer an adjunctive measure to conventional therapies in preventing graft rejection in high-risk corneal transplantation.

Original languageEnglish (US)
Pages (from-to)2411-2417
Number of pages7
JournalInvestigative Ophthalmology and Visual Science
Volume51
Issue number5
DOIs
StatePublished - May 1 2010
Externally publishedYes

Fingerprint

Transplants
Corneal Transplantation
Corneal Neovascularization
Therapeutics
Transplantation
Control Groups
Bevacizumab
Homologous Transplantation
Graft Rejection
Graft Survival
Cornea
Sutures

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Dastjerdi, M. H., Saban, D. R., Okanobo, A., Nallasamy, N., Sadrai, Z., Chauhan, S. K., ... Dana, R. (2010). Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Investigative Ophthalmology and Visual Science, 51(5), 2411-2417. https://doi.org/10.1167/iovs.09-3745

Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. / Dastjerdi, Mohammad H.; Saban, Daniel R.; Okanobo, Andre; Nallasamy, Nambi; Sadrai, Zahra; Chauhan, Sunil K.; Hajrasouliha, Amir R.; Dana, Reza.

In: Investigative Ophthalmology and Visual Science, Vol. 51, No. 5, 01.05.2010, p. 2411-2417.

Research output: Contribution to journalArticle

Dastjerdi, MH, Saban, DR, Okanobo, A, Nallasamy, N, Sadrai, Z, Chauhan, SK, Hajrasouliha, AR & Dana, R 2010, 'Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival', Investigative Ophthalmology and Visual Science, vol. 51, no. 5, pp. 2411-2417. https://doi.org/10.1167/iovs.09-3745
Dastjerdi, Mohammad H. ; Saban, Daniel R. ; Okanobo, Andre ; Nallasamy, Nambi ; Sadrai, Zahra ; Chauhan, Sunil K. ; Hajrasouliha, Amir R. ; Dana, Reza. / Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. In: Investigative Ophthalmology and Visual Science. 2010 ; Vol. 51, No. 5. pp. 2411-2417.
@article{12b9ab0f316b4aeda6ca929ed7d4fbb9,
title = "Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival",
abstract = "Purpose. To investigate whether corneal graft survival could be improved by topical or subconjunctival bevacizumab in a murine model of vascularized high-risk corneal transplantation. Methods. Before corneal transplantation, intrastromal sutures were placed for 2 weeks in the corneas of BALB/c mice, inducing intense angiogenesis. Allogeneic corneal transplantation was performed using C57BL/6 donor mice. Topical bevacizumab (2.5{\%}) was delivered 3 times a day for 3 weeks in one treatment group, and 0.02 mL (0.5 mg) bevacizumab was injected subconjunctivally at days 0, 4, 8, and 15 after transplantation in the other treatment group. The control group received no treatment. Grafts were examined twice a week for 8 weeks by slit-lamp microscopy and were photographed once a week by slit-lamp digital camera and scored for opacity. For assessment of corneal neovascularization (NV), a quantitative method was used to measure three primary metrics including neovascular area, vessel caliber, and neovessel invasion area. Results. Both topical and subconjunctival bevacizumab treatment reduced neovascular area and vessel caliber; however, the regression of corneal NV was more profound when treated subconjunctivally. The mean percentage reduction of neovascular area was 55{\%} (P < 0.05) by week 8 in the subconjunctival treatment group and 33{\%} (P=0.15) in the topical group. Only subconjunctival bevacizumab treatment resulted in significant regression of neovessel invasion area (P < 0.05). All corneal transplants in both the control and the topical groups were rejected by 4 weeks after transplantation. However, in the subconjunctival treatment group, 33{\%} of corneal grafts survived (P < 0.01). Conclusions. Subconjunctival bevacizumab may offer an adjunctive measure to conventional therapies in preventing graft rejection in high-risk corneal transplantation.",
author = "Dastjerdi, {Mohammad H.} and Saban, {Daniel R.} and Andre Okanobo and Nambi Nallasamy and Zahra Sadrai and Chauhan, {Sunil K.} and Hajrasouliha, {Amir R.} and Reza Dana",
year = "2010",
month = "5",
day = "1",
doi = "10.1167/iovs.09-3745",
language = "English (US)",
volume = "51",
pages = "2411--2417",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival

AU - Dastjerdi, Mohammad H.

AU - Saban, Daniel R.

AU - Okanobo, Andre

AU - Nallasamy, Nambi

AU - Sadrai, Zahra

AU - Chauhan, Sunil K.

AU - Hajrasouliha, Amir R.

AU - Dana, Reza

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Purpose. To investigate whether corneal graft survival could be improved by topical or subconjunctival bevacizumab in a murine model of vascularized high-risk corneal transplantation. Methods. Before corneal transplantation, intrastromal sutures were placed for 2 weeks in the corneas of BALB/c mice, inducing intense angiogenesis. Allogeneic corneal transplantation was performed using C57BL/6 donor mice. Topical bevacizumab (2.5%) was delivered 3 times a day for 3 weeks in one treatment group, and 0.02 mL (0.5 mg) bevacizumab was injected subconjunctivally at days 0, 4, 8, and 15 after transplantation in the other treatment group. The control group received no treatment. Grafts were examined twice a week for 8 weeks by slit-lamp microscopy and were photographed once a week by slit-lamp digital camera and scored for opacity. For assessment of corneal neovascularization (NV), a quantitative method was used to measure three primary metrics including neovascular area, vessel caliber, and neovessel invasion area. Results. Both topical and subconjunctival bevacizumab treatment reduced neovascular area and vessel caliber; however, the regression of corneal NV was more profound when treated subconjunctivally. The mean percentage reduction of neovascular area was 55% (P < 0.05) by week 8 in the subconjunctival treatment group and 33% (P=0.15) in the topical group. Only subconjunctival bevacizumab treatment resulted in significant regression of neovessel invasion area (P < 0.05). All corneal transplants in both the control and the topical groups were rejected by 4 weeks after transplantation. However, in the subconjunctival treatment group, 33% of corneal grafts survived (P < 0.01). Conclusions. Subconjunctival bevacizumab may offer an adjunctive measure to conventional therapies in preventing graft rejection in high-risk corneal transplantation.

AB - Purpose. To investigate whether corneal graft survival could be improved by topical or subconjunctival bevacizumab in a murine model of vascularized high-risk corneal transplantation. Methods. Before corneal transplantation, intrastromal sutures were placed for 2 weeks in the corneas of BALB/c mice, inducing intense angiogenesis. Allogeneic corneal transplantation was performed using C57BL/6 donor mice. Topical bevacizumab (2.5%) was delivered 3 times a day for 3 weeks in one treatment group, and 0.02 mL (0.5 mg) bevacizumab was injected subconjunctivally at days 0, 4, 8, and 15 after transplantation in the other treatment group. The control group received no treatment. Grafts were examined twice a week for 8 weeks by slit-lamp microscopy and were photographed once a week by slit-lamp digital camera and scored for opacity. For assessment of corneal neovascularization (NV), a quantitative method was used to measure three primary metrics including neovascular area, vessel caliber, and neovessel invasion area. Results. Both topical and subconjunctival bevacizumab treatment reduced neovascular area and vessel caliber; however, the regression of corneal NV was more profound when treated subconjunctivally. The mean percentage reduction of neovascular area was 55% (P < 0.05) by week 8 in the subconjunctival treatment group and 33% (P=0.15) in the topical group. Only subconjunctival bevacizumab treatment resulted in significant regression of neovessel invasion area (P < 0.05). All corneal transplants in both the control and the topical groups were rejected by 4 weeks after transplantation. However, in the subconjunctival treatment group, 33% of corneal grafts survived (P < 0.01). Conclusions. Subconjunctival bevacizumab may offer an adjunctive measure to conventional therapies in preventing graft rejection in high-risk corneal transplantation.

UR - http://www.scopus.com/inward/record.url?scp=77952514423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952514423&partnerID=8YFLogxK

U2 - 10.1167/iovs.09-3745

DO - 10.1167/iovs.09-3745

M3 - Article

VL - 51

SP - 2411

EP - 2417

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 5

ER -